KaloBios drops lung infection drug, shares plunge

(Reuters) - KaloBios Pharmaceuticals Inc said it would discontinue the development of its drug for lung infections in cystic fibrosis patients after it failed in a mid-stage study, sending the company's shares down 62 percent in extended trading.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news